Back to Search Start Over

Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July–August 2020.

Authors :
Kugeler, Kiersten J.
Podewils, Laura J.
Alden, Nisha B.
Burket, Tori L.
Kawasaki, Breanna
Biggerstaff, Brad J.
Biggs, Holly M.
Zacks, Rachael
Foster, Monique A.
Lim, Travis
McDonald, Emily
Tate, Jacqueline E.
Herlihy, Rachel K.
Drobeniuc, Jan
Cortese, Margaret M.
Source :
Public Health Reports; Jan/Feb2022, Vol. 137 Issue 1, p128-136, 9p
Publication Year :
2022

Abstract

Objectives: The number of SARS-CoV-2 infections is underestimated in surveillance data. Various approaches to assess the seroprevalence of antibodies to SARS-CoV-2 have different resource requirements and generalizability. We estimated the seroprevalence of antibodies to SARS-CoV-2 in Denver County, Colorado, via a cluster-sampled community survey. Methods: We estimated the overall seroprevalence of antibodies to SARS-CoV-2 via a community seroprevalence survey in Denver County in July 2020, described patterns associated with seroprevalence, and compared results with cumulative COVID-19 incidence as reported to the health department during the same period. In addition, we compared seroprevalence as assessed with a temporally and geographically concordant convenience sample of residual clinical specimens from a commercial laboratory. Results: Based on 404 specimens collected through the community survey, 8.0% (95% CI, 3.9%-15.7%) of Denver County residents had antibodies to SARS-CoV-2, an infection rate of about 7 times that of the 1.1% cumulative reported COVID-19 incidence during this period. The estimated infection-to-reported case ratio was highest among children (34.7; 95% CI, 11.1-91.2) and males (10.8; 95% CI, 5.7-19.3). Seroprevalence was highest among males of Black race or Hispanic ethnicity and was associated with previous COVID-19–compatible illness, a previous positive SARS-CoV-2 test result, and close contact with someone who had confirmed SARS-CoV-2 infection. Testing of 1598 residual clinical specimens yielded a seroprevalence of 6.8% (95% CI, 5.0%-9.2%); the difference between the 2 estimates was 1.2 percentage points (95% CI, −3.6 to 12.2 percentage points). Conclusions: Testing residual clinical specimens provided a similar seroprevalence estimate yet yielded limited insight into the local epidemiology of COVID-19 and might be less representative of the source population than a cluster-sampled community survey. Awareness of the limitations of various sampling strategies is necessary when interpreting findings from seroprevalence assessments. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00333549
Volume :
137
Issue :
1
Database :
Complementary Index
Journal :
Public Health Reports
Publication Type :
Academic Journal
Accession number :
154341253
Full Text :
https://doi.org/10.1177/00333549211055137